echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Single-base editing technology for chronic hepatitis B virus infection shows functional healing potential

    Single-base editing technology for chronic hepatitis B virus infection shows functional healing potential

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Beam Therapeutics announced that its preclinical research results show that its cytosine base editor (CBE) in an in vitro model reduces the expression of hepatitis B virus surface antigen (HBsAg) and prevents the level of hepatitis B virus from rebounding after antiviral drugs are stopped.


    Chronic hepatitis B virus (HBV) infection can increase the risk of life-threatening health problems such as liver cirrhosis, liver failure, and liver cancer


    Image source: Beam's official website

    The base editor can convert a specific base into another base without causing a double-strand break


    ▲Using base editing to functionally cure hepatitis B (picture source: Beam Therapeutics official website)

    In in vitro experiments, the researchers screened out two guide RNAs (gRNAs) that target the HBV genome and used them to mediate the introduction of stop codons at different locations in the HBV genome


    ▲Base editing successfully reduced a variety of HBV virus indicators (picture source: Beam Therapeutics official website)

    Combining base editing with the standard antiviral drug lamivudine further increases the efficiency of base editing by 20%, resulting in a higher antiviral effect


    ▲Single-base editing prevents the rebound of virus levels after lamivudine is stopped (Image source: Beam Therapeutics official website)

    Based on this result, Beam plans to conduct a proof-of-concept study on the base editing treatment of chronic hepatitis B in an in vivo model


    Reference materials:

    [1] Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection.


    [2] cccDNA inactivation using cytosine base editors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.